Quality Of Life Assessment And The Related Factors Of Patients With Ankylosing Spondylitis

Part I:Quality of life assessment and the related factors of patients with ankylosing spondylitisObjective The aim of this study was to assess functional disability and quality of life of patients with ankylosing spondylitis and determine the correlation between functional disability and disease activity.Methods The study enrolled 34 patients with ankylosing spondylitis. The demographic data of the patients were collected. Functional disability was assessed with the Bath Ankylosing Functional Index (BASFI). Disease activity was measured with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI).The correlation between the quality of life and the clinical and laboratory measures of disease.Results In our study, occipital wall distance, modified Schober test, chest expansion, FJoor-finger tip distance, TNF-α, and CRP showed significant correlation with BASDAI and BASFI (all P<0.01).BASFI was significantly correlated with BASDAI (r=0.998). BASDAI and BASFI were negatively correlated with ESR respectively.Conclusion BASFI scores had significant negative correlations with BASDAI scores, modified Schober test, TNF-a, and CRP were helpful to assess the function status and disease activity. Ankylosing spondylitis disease activity had significantly correlated with TNF-αand CRP but not ESR. PartⅡ:Treatment of ankylosing spondylitis with a recombinant human tumor necrosis factor receptor-Fc fusion protein:a short-term clinical studyObjective To evaluate the short-term efficacy and safety profile of a recombinant human tumor necrosis factor receptor-Fc fusion protein in ankylosing spondylitis(AS).Methods This was is a retrospective study. The study enrolled 34 patients with ankylosing spondylitis. All patients were assigned to receive twice-weekly subcutaneous injections of rh TNFR:Fc. The endpoints were related to reducing signs and symptoms of AS and improving range of motion and physical function.Results In total,34 patients were included. Treatment with rhTNF:Fc results in significant improvement. Improvement over baseline values for the measures of disease activity and function ability were great significant. rhTNF:Fc was well tolerated, The most frequently treatment related adverse events is upper respiratory tract infection. Most related adverse events were mild.Conclusion rhTNF:Fc has demonstrated consistent evidence of efficacy and is well tolerated in the treatment of AS.